Subcutaneous blinatumomab plus ponatinib for Ph+ B-cell ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). One drug is given as a shot under the skin, the other as a pill, to help kill leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have Ph+ B-ALL with CD19 positive cells.
- You have not received any prior treatment for your leukemia (a short course of steroids or hydroxyurea is okay).
- You must have at least 5% leukemia cells in your bone marrow.
- Your organs (liver, pancreas, kidneys, heart) must work well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—together for people with a specific genetic type of acute lymphoblastic leukemia (Ph+ or BCR::ABL1-positive). The goal is to see how well the combination works for both newly diagnosed and relapsed/refractory cases.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a subcutaneous (under the skin) form of blinatumomab for people with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of leukemia cells that can be detected by sensitive tests. The goal is to see if this treatment is safe and can get rid of those remaining cells.
This trial tests a new combination of four drugs (LP-118, ponatinib, dexamethasone, and blinatumomab) to treat a specific type of blood cancer called Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL). The study aims to see if this combination is safe and effective in newly diagnosed adults.
This trial tests a lower dose of chemotherapy followed by 14 days of blinatumomab for adults newly diagnosed with a type of leukemia called B-ALL. The goal is to see if this approach works well and reduces side effects.
Hear when a new Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.